Best Practice & Research Clinical Haematology
Vol. 32, No. 2, pp. I, 2019

Keyword Index

Acute myeloid leukemia (AML), 116, 134
Acute myeloid leukemia, 127, 145, 154, 163, 177
Acute myeloid leukemia with myelodysplastic related changes, 127
Allogeneic stem cell transplantation, 186
AML, 186
Antibody-drug conjugate, 116
ARCH, 177

Bone marrow failure, 163

CHIP, 177
Clinical trials, 127
Clonal hematopoiesis, 177
Consolidation, 127
CPX-351, 127
Crenolanib, 154
Cytopenia, 127

Familial, 163
FLT3 inhibitor, 154
FLT3 mutations, 154
Frontline therapy, 154

Genetic, 163
Germline, 163
Gilteritinib, 154

Hereditary, 163
Hypomethylating agents, 145

(radio)immunotherapy, 116
Immunotoxin, 116
Induction, 127

Leukemic stem cells, 186
Liposomal daunorubicin:cytarabine, 127
Liposomal drug, 127
Liposome, 127
Low-intensity chemotherapy, 145

Measurable residual disease (MRD), 186
Midostaurin, 154
Monoclonal antibody, 116
Multicolor flowcytometry, 186
Myelodysplastic syndrome, 163, 177

p388, 127
Predisposition, 163

qPCR, 186
Quizartinib, 154

Secondary acute myeloid leukemia, 127

therapy-related acute myeloid leukemia (t-AML), 134
TP53, 134

Venetoclax, 145
Vyxeos, 127